Quoin Pharmaceuticals Ltd ((QNRX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quoin Pharmaceuticals Ltd is conducting a study titled ‘A Multicenter, Randomized, Vehicle-Controlled, Double-Blind, Parallel Comparison Study of QRX003 Lotion in Subjects With Netherton Syndrome.’ The study aims to evaluate the safety, tolerability, and efficacy of QRX003 lotion in treating Netherton Syndrome, a rare genetic skin disorder. This research is significant as it could offer a new treatment option for patients with limited alternatives.
The study tests QRX003 lotion in different concentrations and application frequencies, including 2% and 4% solutions applied once or twice daily. The lotion contains a serine protease inhibitor intended to alleviate symptoms of Netherton Syndrome.
This interventional study employs a randomized, parallel assignment model with triple masking, meaning participants, care providers, and investigators are unaware of which treatment is administered. The primary goal is treatment efficacy.
The study began on August 17, 2022, with an estimated primary completion date not yet disclosed. The latest update was submitted on March 28, 2025, indicating ongoing progress.
The outcome of this study could influence Quoin Pharmaceuticals’ stock performance and investor sentiment, especially if the results show a significant improvement in treating Netherton Syndrome. This could position Quoin favorably against competitors in the dermatological treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.